Heilongjiang ZBD Pharmaceutical Co Ltd
Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in China. It offers cardiovascular and cerebrovascular, respiratory system, orthopedics, tumors, digestive system, anti-infection, mental nerve, genitourinary, and other disease fields. The company was founded in 1996 and is based in Hulin, China.
Market Cap & Net Worth: Heilongjiang ZBD Pharmaceutical Co Ltd (603567)
Heilongjiang ZBD Pharmaceutical Co Ltd (SHG:603567) has a market capitalization of $974.70 Million (CN¥7.15 Billion) as of March 19, 2026. Listed on the SHG stock exchange, this China-based company holds position #11645 globally and #2776 in its home market, demonstrating a 1.06% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Heilongjiang ZBD Pharmaceutical Co Ltd's stock price CN¥7.60 by its total outstanding shares 940996515 (941.00 Million).
Heilongjiang ZBD Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Heilongjiang ZBD Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $3.04 Billion to $974.70 Million (-8.59% CAGR).
Heilongjiang ZBD Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Heilongjiang ZBD Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.55x
Heilongjiang ZBD Pharmaceutical Co Ltd's market cap is 0.55 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
3.39x
Heilongjiang ZBD Pharmaceutical Co Ltd's market cap is 3.39 times its annual earnings
10.35x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.04 Billion | $2.07 Billion | $585.31 Million | 1.47x | 5.20x |
| 2016 | $2.37 Billion | $2.39 Billion | $509.56 Million | 0.99x | 4.66x |
| 2017 | $1.72 Billion | $3.14 Billion | $520.87 Million | 0.55x | 3.29x |
| 2018 | $1.47 Billion | $2.78 Billion | $462.44 Million | 0.53x | 3.19x |
| 2019 | $1.59 Billion | $3.29 Billion | $408.65 Million | 0.48x | 3.88x |
| 2020 | $1.42 Billion | $3.40 Billion | $436.29 Million | 0.42x | 3.25x |
| 2021 | $1.94 Billion | $4.13 Billion | $332.10 Million | 0.47x | 5.84x |
| 2022 | $1.63 Billion | $4.21 Billion | $185.44 Million | 0.39x | 8.80x |
| 2023 | $1.56 Billion | $3.14 Billion | $472.74 Million | 0.50x | 3.30x |
| 2024 | $1.49 Billion | $2.70 Billion | $438.22 Million | 0.55x | 3.39x |
Competitor Companies of 603567 by Market Capitalization
Companies near Heilongjiang ZBD Pharmaceutical Co Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to Heilongjiang ZBD Pharmaceutical Co Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Heilongjiang ZBD Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Heilongjiang ZBD Pharmaceutical Co Ltd's market cap moved from $3.04 Billion to $ 974.70 Million, with a yearly change of -8.59%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥974.70 Million | -14.89% |
| 2025 | CN¥1.15 Billion | -23.02% |
| 2024 | CN¥1.49 Billion | -4.61% |
| 2023 | CN¥1.56 Billion | -4.46% |
| 2022 | CN¥1.63 Billion | -15.90% |
| 2021 | CN¥1.94 Billion | +37.10% |
| 2020 | CN¥1.42 Billion | -10.82% |
| 2019 | CN¥1.59 Billion | +7.76% |
| 2018 | CN¥1.47 Billion | -14.15% |
| 2017 | CN¥1.72 Billion | -27.70% |
| 2016 | CN¥2.37 Billion | -22.00% |
| 2015 | CN¥3.04 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Heilongjiang ZBD Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $974.70 Million USD |
| MoneyControl | $974.70 Million USD |
| MarketWatch | $974.70 Million USD |
| marketcap.company | $974.70 Million USD |
| Reuters | $974.70 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.